comprehensive -WSS

comprehensive

author：hotspot 2025-09-30 00:36:30 - browse：624

Micrograph of ulcerative colitis -- biotech coverage from STAT — Micrograph of chronic active ulcerative colitis in a biopsy specimen. Wikimedia Commons

Checkpoint inhibitors, drugs that unleash the immune system, have turned into blockbuster therapies that have transformed outcomes for some patients with deadly cancers. AltruBio, a Bay Area biotech, is betting it can help patients suffering from autoimmune and inflammatory diseases by taking the opposite tack: pumping the brakes on runaway immune responses.

The company on Tuesday announced that it has raised $225 million in a Series B venture round led by BVP Partners, with the biotech’s backers also including RA Capital Management, Cormorant Asset Management, and Soleus Capital. AltruBio plans to put that money toward advancing a drug that is already being tested in a mid-stage trial for ulcerative colitis, an increasingly competitive market in which a number of pharma companies have launched drugs.

It’s the latest example of intense investor interest in immunology-focused companies. Firms such as Paragon Therapeutics and Prometheus Laboratories have recently been at the center of financing mega-rounds, and Blackstone Life Sciences recently committed up to $300 million to launch Uniquity Bio, a company developing treatments for asthma and chronic obstructive pulmonary disease.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Guidelines to prevent youth baseball injuries need more muscle
Next article： Eli Lilly reports tirzepatide MASH success during Q4 earnings

Wikipedia

WSS

Why Eli Lilly’s earnings didn’t quite live up to the hype

Doctors on social media are being harassed and cyberbullied

Cognito secures funding to test medical device for Alzheimer's

Bernie Sanders gets little from pharma CEOs on drug prices

Vertex non

Abbott's new heart device gets FDA advisory panel nod

entertainment

comprehensive

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

explore

Sports medicine is finally prioritizing gender equality

Readout Newsletter: Replicate, Biogen's Leqembi, and Humira

Apple is now the first public company to be valued at $3 trillion

Woodcock on FDA’s accelerated approval and her next chapter

United colonoscopy coverage change 'may cost lives,' doctors say

Study gives hint on South Asians’ higher risk of cardiovascular disease

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Vertex non

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Lilly to acquire Dermira for $1.1 billion, adding eczema drug to its pipeline

focus

In a test for AI, buzzy startup Insitro inks drug discovery deal with Gilead

ACIP vaccine advisory panel sees its vacancies filled

Abbott's new heart device gets FDA advisory panel nod

Readout Newsletter: Vertex, Biogen's Aduhelm, and Bristol updates

In a test for AI, buzzy startup Insitro inks drug discovery deal with Gilead

In a test for AI, buzzy startup Insitro inks drug discovery deal with Gilead

Wikipedia

Wikipedia

Wikipedia

focus